Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Gross Margin (2019 - 2025)

Coherus Oncology's Gross Margin history spans 7 years, with the latest figure at 68.27% for Q4 2025.

  • For Q4 2025, Gross Margin fell 100119.0% year-over-year to 68.27%; the TTM value through Dec 2025 reached 67.24%, down 10848.0%, while the annual FY2025 figure was 67.24%, 31.0% up from the prior year.
  • Gross Margin for Q4 2025 was 68.27% at Coherus Oncology, up from 67.84% in the prior quarter.
  • Across five years, Gross Margin topped out at 1069.46% in Q4 2024 and bottomed at 7.6% in Q4 2023.
  • The 5-year median for Gross Margin is 68.48% (2025), against an average of 115.48%.
  • The largest annual shift saw Gross Margin surged 106185bps in 2024 before it plummeted -100119bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 83.5% in 2021, then dropped by -18bps to 68.68% in 2022, then tumbled by -89bps to 7.6% in 2023, then surged by 13969bps to 1069.46% in 2024, then crashed by -94bps to 68.27% in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Gross Margin are 68.27% (Q4 2025), 67.84% (Q3 2025), and 66.89% (Q2 2025).